Ventyx Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTYX research report →
Companywww.ventyxbio.com
Ventyx Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.
- CEO
- Sheila K. Gujrathi
- IPO
- 2021
- Employees
- 81
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $1.00B
- P/E
- -9.36
- P/S
- 0.00
- P/B
- 5.22
- EV/EBITDA
- -8.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -48.11%
- ROIC
- -57.96%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-135,122,000 · 29.97%
- EPS
- $-1.97 · 40.30%
- Op Income
- $-148,450,000
- FCF YoY
- 21.51%
Performance & Tape
- 52W High
- $25.00
- 52W Low
- $0.78
- 50D MA
- $12.84
- 200D MA
- $6.40
- Beta
- 1.27
- Avg Volume
- 3.81M
Get TickerSpark's AI analysis on VTYX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 26 | Gonzales Roy | sell | 5,313 |
| Mar 4, 26 | Gonzales Roy | sell | 37,500 |
| Mar 4, 26 | Gonzales Roy | sell | 70,000 |
| Mar 4, 26 | Gonzales Roy | sell | 12,500 |
| Mar 4, 26 | Gonzales Roy | sell | 35,000 |
| Mar 4, 26 | Subramaniam Somu | sell | 15,937 |
| Mar 4, 26 | Subramaniam Somu | sell | 40,000 |
| Mar 4, 26 | Subramaniam Somu | sell | 3,337,495 |
| Mar 4, 26 | Subramaniam Somu | sell | 33,000 |
| Mar 4, 26 | Subramaniam Somu | sell | 20,000 |
Our VTYX Coverage
We haven't published any research on VTYX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VTYX Report →